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Abstract
Background
The epidermal growth factor receptor (EGFR) is overexpressed in many cancers including
lung, ovarian, breast, head and neck and brain. Mutation of this receptor has been shown to
play a crucial role in the response of non-small cell lung carcinoma (NSCLC) to EGFR-tar-
geted therapies. It is envisaged that imaging of EGFR using positron emission tomography
(PET) could aid in selection of patients for treatment with novel inhibitors. We recognised
multi-drug resistant phenotype as a threat to development of successful imaging agents.
In this report, we describe discovery of a novel cyanoquinoline radiotracer that lacks ABC
transporter activity.
Methods
Cellular retention of the prototype cyanoquinoline [18F](2E)-N-{4-[(3-chloro-4-fluorophenyl)
amino]-3-cyano-7-ethoxyquinolin-6-yl}-4-({[1-(2-fluoroethyl)-1H-1,2,3-triazol-4-yl]methyl}
amino)-but-2-enamide ([18F]FED6) and [18F](2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-3-
cyano-7-ethoxyquinolin-6-yl}-4-[({1-[(2R,5S)-3-fluoro-4,5-dihydroxy-6-(hydroxymethyl)
oxan-2-yl]-1H-1,2,3-triazol-4-yl}methyl)amino]but-2-enamide ([18F]FED20) were evaluated
to establish potential for imaging specificity. The substrate specificity of a number of cyano-
quinolines towards ABC transporters was investigated in cell lines proficient or deficient in
ABCB1 or ABCG2.
Results
FED6 demonstrated substrate specificity for both ABCG2 and ABCB1, a property that was
not observed for all cyanoquinolines tested, suggesting scope for designing novel probes.
ABC transporter activity was confirmed by attenuating the activity of transporters with drug
inhibitors or siRNA. We synthesized a more hydrophilic compound [18F]FED20 to overcome
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ABC transporter activity. FED20 lacked substrate specificity for both ABCB1 and ABCG2,
and maintained a strong affinity for EGFR. Furthermore, FED20 showed higher inhibitory
affinity for active mutant EGFR versus wild-type or resistant mutant EGFR; this property
resulted in higher [18F]FED20 cellular retention in active mutant EGFR expressing NSCLC.
Conclusion
[18F]FED20 binds EGFR but is devoid of ABC transporter activity, thus, has potential for
EGFR imaging.
Introduction
The epidermal growth factor receptor (EGFR) is a 170 kDA transmembrane tyrosine kinase
receptor member of the ErbB family of receptors, which includes HER2 (ErbB2), HER3
(ErbB3) and HER4 (ErbB4) [1]. Pathological expression of EGFR has been observed in many
cancers including head and neck, breast, pancreatic, non-small cell lung cancer (NSCLC) and
colorectal cancers [2]. Currently clinically approved therapies which target EGFR include
monoclonal antibodies such as cetuximab or panitumumab [3,4], and small molecular tyrosine
kinase inhibitors (TKI) such as gefitinib and erlotinib [4]. In the context of NSCLC, the efficacy
of TKI’s was found to be significantly higher in patients who express active mutant EGFR of
which the L588R and Del E746-A750 mutations are the most common. The frequency of
mutations in EGFR recorded in NSCLC patients has been found to vary [5–7], but can be as
high as 44% in female Asian patients with adenocarcinoma and no previous history of smoking
[5,8,9]. The Iressa Pan-Asia-Study (IPASS), which compared gefitinib to a standard carbopla-
tin and paclitaxel chemotherapy in a first line treatment setting in NSCLC Asian patients [10]
was the first study that demonstrated a benefit of TKI therapy in selected NSCLC patients. The
most prevalent mechanism of acquired resistance is a secondary mutation in EGFR (T790M);
this mutation occurs in half of patients administered reversible TKIs and results from an
increase in affinity for the receptor for ATP [11,12]. The issue of acquired resistance is com-
plex; more recently C797S mutations were reported as a new mechanism to third generation
TKIs [13]. Despite advances in EGFR targeted therapies and the increasing number of EGFR
inhibitors undergoing preclinical evaluation, there are currently no non-invasive probes for the
in vivo imaging of EGFR used routinely in the clinical setting. Such probes could be used to aid
patient stratification in a setting where multiple biopsies are difficult to obtain.
A number of positron emission tomography (PET) probes targeting EGFR have been devel-
oped and preclinically evaluated in the last decade. Both gefitinib and erlotinib have been
radiolabelled with carbon-11 and/or fluorine-18. [18F]Gefitinib gave disappointing results as
no differences were detected in vitro or in vivo in models that expressed different levels of
EGFR or mutant forms of EGFR [14]. On the other hand [11C]erlotinib showed more promis-
ing results in vivo, with higher uptake in active mutant EGFR compared to wild type EGFR
expressing xenografts [15]. Furthermore, a clinical trial evaluating the use of [11C]erlotinib for
the in vivo assessment of EGFR mutational status in NSCLC patients have been published [16].
This small trial of five patients with del E746-A750 and five patients with WT EGFR showed
that the volume of distribution of the radiotracer was on average two times greater in the del
E746-A750 EGFR than in the wild-type EGFR expressing tumours [16].
Other EGFR targeting radiotracers have been developed based on irreversible TKIs, which
covalently bind cysteine-773 of the EGFR tyrosine kinase-binding site. Irreversible tracers were
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believed to be more appropriate for in vivo imaging as they would compete less with the high
intracellular ATP concentration for domain occupancy [17]. One of the first compounds of
this series was [18F]ML04, which although retained selectivity for EGFR in vitro was poorly
specific in vivo, with high uptake in EGFR negative tumour models and no decrease in tumour
radioactivity upon pre-treatment with a blocking dose of cold ML04 [17]. Our group developed
fluorine-18 labelled cyanoquinoline irreversible probes including FED6 ([18F](2E)-N-{4-
[(3-chloro-4-fluorophenyl)amino]-3-cyano-7-ethoxyquinolin-6-yl}-4-({[1-(2-fluoroethyl)-
1H-1,2,3-triazol-4-yl]methyl}amino)-but-2-enamide; Fig 1) [18]. FED6 showed high uptake in
EGFR overexpressing tumours compared to low EGFR expressing tumours and was metaboli-
cally stable. There were however high levels of uptake in the intestines. This was partially attrib-
uted to less favourable pharmacokinetics and/or non-specific interactions. In the context of
PET imaging of mutant forms of EGFR, one of the first examples of irreversible TKI reported
in the literature is [18F]PEG6-IPQA; [18F]PEG6-IPQA was shown to bind with higher selectiv-
ity and specificity to L858R activating mutant EGFR expressing tumour xenografts compared
to resistant EGFR L858R/T790M mutant xenografts [19]. More recently, Slobbe and co-work-
ers have demonstrated potential usefulness of [18F]afatinib as an irreversible TKI for imaging
treatment-sensitive xenografts harboring exon-19 deletion mutations in EGFR [20].
One of the threats to use of quinoline or quinazoline-based molecules as imaging agents is
susceptibility to efflux by members of the ATP binding cassette transporter proteins (ABC
transporters) overexpressed at the cell surface of most tumours [21]. The key ABC transporter
family members of relevance to the multi-drug resistance (MDR) phenotype in oncology
include permeability glycoprotein (P-gp also known as ABCB1), breast cancer resistance pro-
tein (BCRP or ABCG2) and multidrug resistance protein 1 (MRP1or ABCC1) [21,22]. In
relation to probe design, compounds that are substrates for ABCB1 despite having different
structures share certain physicochemical properties such as a molecular weight (MW)> 400
Da, logP> 3 and polar surface area (PSA)> 85 Å2 [23]. Both gefitinib and erlotinib have been
found to be substrates of ABCB1 and ABCG2 [24,25]; furthermore, gefitinib has also been
shown to be an inhibitor of ABCG2 [22]. Second generation irreversible inhibitors including
EKB-569 (pelitinib; Fig 1) from which the cyanoquinoline series of compound was based, also
interact with ABCG2 [24]. Regarding EGFR targeted radiotracers, [18F]ML04 was found to be
a substrate for ABCB1 [17]; more recently [18F]afatinib was also shown to be responsive to
ABCB1 modulation [20]. The threat posed by ABC substrate specificity for imaging probes
results from the low mass of injected compound resulting in efficient efflux and consequently
low tumour localisation. Against this background, we investigated the interaction of a series of
cyanoquinolines EGFR antagonists previously evaluated in our laboratory for their substrate
specificity for key ABC transporters, ABCB1 and ABCG2. Based on the findings, we tested a
new probe and found it to be devoid of ABC transporter substrate specificity.
Materials and Methods
Inhibitors and Cell Lines
Unless otherwise stated, all compounds were purchased from Sigma (St Louis, Missouri, USA).
For brevity, cell lines used to investigate ABC transporter specificity, together with their respec-
tive growth media are summarised in Table 1. 3T3 and 3T3 transfected with cDNA expressing
P-gp (pHamdr1) were kindly provided by Dr E Schuetz from St Jude’s Children Research
Hospital (Memphis, TN, USA) [26], and MCF7 and mitoxantrone (MX)-resistant subclones
MCF7MX by Dr E Schneider from the University of Maryland (Baltimore, MD, USA) [27].
Generation of the isogenic PC9ER from PC9 lung cancer cells has been reported [28]. Media
were supplemented with 1% penicillin/streptomycin and 10% fetal bovine serum (FBS) (all
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purchased from Invitrogen, Carlsbad, California, USA). All cells were grown in a humidified
atmosphere at 37°C and 5% CO2.
Inhibition of EGFR Autophosphorylation
Affinity of the cyanoquinolines for EGFR was established by measuring their inhibition of
EGFR autophosphorylation via western blot. Cells were seeded in 6 well plates and following
24 h of growth, were subject to overnight serum starvation. The cells were then treated with
increasing concentrations of cyanoquinolines prepared in serum free growth media from a
DMSO stock (final DMSO concentration< 1%) for 3 h at 37°C, and stimulated for receptor
Fig 1. Physicochemical properties of cyanoquinoline compounds.Molecular weight (MW), the sum of oxygen and nitrogen atoms
(N+O), calculated Log P (Marvin Sketch; https://www.chemaxon.com/products/marvin/marvinsketch), and polar surface area (PSA).
LogarIthmic value of acid dissociation constant (pKA).
doi:10.1371/journal.pone.0161427.g001
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autophosphorylation by addition of 100 ng/mL of EGF during the last 15 minutes of drug incu-
bation. After 3 h the cells were placed on ice, media removed and then the cells were washed
two times with ice cold phosphate buffered saline (PBS). Lysates were analysed by western blot
to measure changes to p-EGFR Y1068.
Western Blot Analysis
Cell lysates were prepared by addition of radioimmunoprecipitation assay (RIPA) buffer
(50mM Tris-HCl pH 7.2, 150mMNaCl, 1% NP40, 1% sodium deoxycholate, 0.1% sodium
dodecyl sulfate) supplemented with 1 x protease and phosphatase inhibitor cocktail (1mM 4-
(2-Aminoethyl)benzenesulfonylfluoride hydrochloride, 800 nM aprotinin, 50 μM bestatin,
15 μM E-64, 5μM EDTA, 20 μM leupeptin, 10 μM pepstatin A; Thermo scientific, Waltham,
Massachusetts, USA). Cells were collected into a microcentrifuge tube and sonicated for 30 sec-
onds on ice. Cellular protein levels were assessed using a bicinchoninic acid (BCA) protein
assay kit according to the manufacturer’s instructions (Thermo scientific). Lysates containing
10 x reducing agent (Invitrogen) and 4x NuPAGE1 LDS Sample Buffer (4X) (lithium dodecyl
sulphate) (Invitrogen) were denatured by heating for 10 minutes at 70°C; 15 μg of the protein
samples were separated using 4–15% polyacrylamide Mini-PROTEAN TGX precast gels (Bio-
Rad, Hemel Hempstead, UK). Samples were transferred to polyvinylidene difluoride (PVDF)
membrane using Trans-Blot Turbo system BIO-RAD (Hercules, California, USA). Membranes
were blocked with 5% milk or 5% bovine serum albumin (BSA) in Tris-buffered saline-tween
20 (TBST; 50 mM Tris, 150 nM NaCl, 0.05% tween 20) for 1 h at room temperature. The mem-
branes were then incubated overnight with primary antibody prepared in 1% milk or 1%
BSA in TBST. Primary antibody (antibody, source, catalog number, antibody dilution): p-
EGFR-Y1068, Cell Signaling Technology, 2234, 1/1000; EGFR, Cell Signaling Technology,
2232, 1/2000; ABCG2, Abcam, ab3380, 1/1000; ABCB1, Abcam, ab129450, 1/1000; b-actin,
Sigma, SAB5500001, 1/5000. After overnight incubation, membranes were washed three times
for 10 minutes with TBST before incubating with secondary goat anti-rabbit (Sc-2004) or goat
anti-mouse (Sc-2005) antibody (Santa Cruz Biotechnology, Dallas, Texas, USA) at 1/2000
dilution for 1 h at room temperature. Membranes were washed a further three times for 10
minutes with TBST. Blots were visualised using chemoluminescence (ECL, GE Healthcare,
Table 1. Summary of cell lines used.
Cell line Source EGFRmutation status Other genes Growth media
H1650 ATCC Del E746-A750 PTEN null RPMI
H358 ATCC WT RPMI
A549 ATCC WT k-RAS mutant RPMI
H3255 ATCC L858R RPMI
H1975 ATCC L858R/T790M RPMI
PC9 Dr Olivier Pardo, Imperial College London, UK Del E746-A750 RPMI
PC9ER Dr Olivier Pardo, Imperial College London, UK Del E746-A750/T790M RPMI
A431 ATCC WT DMEM
MCF7 Dr E. Schneider, University of Maryland, USA WT DMEM
MCF7MX Dr E. Schneider, University of Maryland, USA WT ABCG2 DMEM
3T3 Dr E. Schuetz, TN USA WT DMEM
3T3-MDR1 Dr E. Schuetz, TN USA WT MDR1 DMEM
WT, wildtype; RPMI, Roswell Park Memorial Institute medium-1640; DMEM, Dulbecco's Modiﬁed Eagle Medium.
doi:10.1371/journal.pone.0161427.t001
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Little Chalfont, UK) and developed on Amersham Hyperfilm ECL (GE Healthcare). β-Actin
was used as a loading control.
Cell Viability Assay
Cell viability by the sulforhodamine B (SRB) assay was used to assess cell growth and cytotoxic-
ity of test compounds [29]. Cells were seeded at densities of 3,500 to 5,000 cells per well in
96 well plates overnight and pre-treated for 1 h with ABC transporter modulators: 10 μM
fumitremorgin C (FTC; in MCF7MX and MCF7 cells), or 0.3 μM of zosuquidar (in 3T3 and
3T3-MDR1). Cells were then treated with test compounds for 72 h, at 37°C. After drug treat-
ment, cells were fixed by addition of 50% trichloroacetic acid (TCA), and the plates washed
and dried to allow staining with 0.4% solution of sulforhodamine B (Sigma) in 1% acetic acid
for 30 minutes. Excess dye was removed upon washing with 1% acetic acid. Plates were dried
and bound protein was solubilised upon addition of 150 μL of 10 mM Tris base buffer. Absor-
bance was measured at 540 nm using Thermo Multiskan-Ex plate reader. Cell viability versus
compound concentration curves were plotted as a percentage of control cells. The concentra-
tion of drug that gave 50% inhibition in cell growth (GI50) was extrapolated from these
curves using the sigmoid curve fit with variable slope in Prism (GraphPad Prism version 5.01,
GraphPad Software, San Diego California USA). Three to six replicate wells were used for each
drug concentration and experiments were carried out on three separate occasions for each
compound.
Caco2 Transwell Assay
The caco2 transwell assay was performed to assess permeability. Cells were seeded at a density
of 60,000 cells per well in 24 well transwell plates (Millipore, Billerica, Massachutsetts, USA),
and maintained in DMEM supplemented with 4.5 g/mL glucose (20% FBS, 1% penicillin/strep-
tomycin, 1% glutamine) for 21 days at 37°C in 5% CO2. After 21 days the cells differentiate
into enterocytes and express all three MDR proteins, ABCB1 and ABCG2 at the apical side and
ABCC1 on the basal side. On day 21, cells were washed three times with Hank's Balanced Salt
Solution (HBSS) (Fisher scientific, Loughborough, UK) and the trans-epithelial electric resis-
tance (TERR) was measured using an Epithelial Voltohmmeter (EVOM) (World Precision
Instruments, Sarasota, USA); only transwells with TERR of 400Ω/cm2 or above were used for
the experiment. Cells were treated either at the apical (n = 3) or basal (n = 3) side of the trans-
well by addition of 10 μM of cyanoquinoline compound or 50 μM vinblastine prepared in a
volume of 400 μL HBSS (compound added to apical well) or 800 μL of HBSS (added to basal
well). When transport inhibitors FTC (10 μM) or zosuquidar (0.3 μM) were used, they were
added to both the apical and basal wells 1 h prior to drug treatment. After 1 h pre-treatment
the medium was removed and cells were treated with the compounds prepared in HBSS con-
taining FTC or Zosuquidar.
Plates were incubated in shaker incubator at 37°C and 60 rpm for 120 min. After incubation,
200 μL aliquots from the apical and the basal wells were collected and analysed using high per-
formance liquid chromatography (HPLC). Samples were run on a Millipore Waters HPLC sys-
tem which included a 717 plus autosampler and 2487 dual wavelength absorbance detector
system. The stationary phase comprised of a Phenomenex Luna C18 reverse phase column (150
X 4.6 mm; 5 μm particle size). The mobile phase comprised water (0.1% TFA) and acetonitrile
(0.1% TFA) (80:20 v/v) at a flow rate of 1 mL/min for all compounds except vinblastine.
For vinblastine, the stationary phase comprised a Supelcosil LC-ABZ reverse phase column
(5 × 4.6 mm; 5 μm particle size). The mobile phase comprised water (0.1% formic acid)
and methanol (90:10 to 10:90 v/v gradient over 20 min). Peak areas corresponding to the
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compounds of interest were recorded. Using standard curves the areas under the curve were
converted into concentrations of compound. The permeability coefficient (Papp) was calcu-
lated using the following equation [30]: Papp = (dQ/dt)/A C0, where A is the surface area of
the transwell membrane in cm2 (= 0.33 cm2), C0 is the drug concentration in the donor cham-
ber at time t = 0 and dQ/dt is the rate of transfer of the compound to the receiver chamber,
determined from the slope of the graph concentration (dQ) versus time (dt). Papp values corre-
sponding to absorption and secretion were assessed and used to calculate efflux ratio.
Efflux ratio ¼ ðPapp B AÞðPapp A BÞ
Where Papp A-B = Papp absorption and Papp B-A = Papp secretion.
The integrity of the caco2 cell membrane was assessed for each well following the experi-
ment by addition of a 100 μM solution of luciferase yellow (Sigma) in HBSS to the apical side
of the plate. The plates were placed in the shaker incubator for 1 h at 37°C and 60 rpm. Samples
from the basal wells were transferred into a 96 well plate and the levels of luciferase yellow were
assessed by measuring with an excitation of 450 nm and an emission of 540 nm using the Per-
kinElmer Wallac 1420 counter. The membrane was considered intact if measured values from
the basal side were inferior to 1% that of the measured values on the apical side.
siRNA Transfection
SiRNA transfections were carried out using ON TARGET plus-SMARTpool siRNA or non-
targeting siRNA (Dharmacon, Lafayette, Louisianna, USA); ABCG2, L-009924-00-0005 and
scramble (non-targeting) D-001810-10-05. Lipofectamine RNAiMAX (Invitrogen UK) was
used as the transfection reagent and was prepared as indicated on the product protocol. Cells
were seeded in black 96 well plates in antibiotic free media. On the day of transfection, siRNA
and Lipofectamine were separately diluted in opti-MEMmedia, mixed in a 1 to 1 ratio and
incubated at room temperature for 20 min; the siRNA-Lipofectamine complexes were then
added to the cells. Fresh media containing 1% penicillin streptomycin was added to the cells
after 24 h followed by Hoechst fluorescent assays at 72 h.
Cell Uptake Assay
[18F]FED6 and [18F]FED20 were synthesised as previously reported [18,31]. To increase spe-
cific radioactivity of [18F]FED20, we modified the synthesis by decreasing the amount of alkyne
precursor from 1 mg down to 0.5 mg. While this had the desired effect of increasing the specific
activity from 7.3 GBq/μmol up to 52 GBq/μmol, the conversion of the alkyne to the triazole
product dropped from> 95% down to 45%. Cells were seeded in 6 well plates and [18F]FED6
(0.22 MBq) or [18F]FED20 (0.55 MBq or 0.74 MBq) added to each well and incubated at 37°C
for 1 h. Media were then removed and cells were washed twice with PBS. The cells were trypsi-
nised and centrifuged for 3 minutes at 2000 rpm to obtain a pellet. The cell pellet was washed
once with PBS and resuspended in 200 μL of RIPA buffer. Cell lysates were transferred to
gamma counting tubes and the radioactivity in the pellet was measured on a Packard Cobra II
gamma counter, (Perkin-Elmer, Waltham, Massachusetts, USA). Protein concentrations of
samples were evaluated using Pierce1 BCA Protein Assay Kit (Thermo Scientific, Waltham,
Massachusetts, USA). Data were expressed as background- and decay-corrected counts per
minute (CCPMA) per μg of cellular protein.
ABC Transporter-Independent Imaging of EGFR
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Statistics
Unless otherwise specified, data were expressed as mean ± standard error (SE). Data were com-
pared by unpaired two tailed Student’s t-test using GraphPad Prism. Statistical significance
was assigned to values 0.05.  corresponded to p value< 0.05 and  corresponded to
p< 0.01.
Results
Cyanoquinoline Compound FED6 Is a Substrate for ABCB1 and ABCG2
As shown in Fig 1, the series of FED compounds possess several of the physico-chemical prop-
erties which are associated with ABCB1 and ABCG2 substrate specificity (MW> 400 Da
(567), PSA> 85Å2 (130 Å2), number of nitrogen and oxygen atoms (N+O)> 8 (10), number
of aromatic rings> 2 (3) and lipophilicity (LogP)< 1 or> 5 (3.85)). The exception to this was
FED14 (synthetic intermediate molecule in the series) [23].
We investigated the substrate specificity of the cyanoquinoline series to the two ABC trans-
porters previously reported to interact with TKI compounds: ABCB1 and ABCG2 by a number
of approaches. First, we used two paired cell models - 3T3 cells (transfected with an empty vec-
tor) and 3T3-MDR1 cells (transfected with the human MDR1 gene which encodes ABCB1) or
MCF7 cells and a mitoxantrone resistant, MCF7MX cell line, which overexpresses ABCG2—
and investigated the impact of FED6 treatment on cell viability. The GI50 (causing 50% growth
inhibition) values obtained from these cell viability assays are summarised in Table 2. EKB-
569, FED2 and FED6 were associated with GI50s of 5.75, 36, and> 100 μM, respectively, in
the 3T3-MDR1 cells; corresponding values in the 3T3 cells were 1.06, 7 and 10.7 μM. Com-
pounds associated with ABC transporter proficient to isogenic ABC transporter deficient cell
line GI50 ratio of> 2 are considered to be actively effluxed by the transporters. There was a
5.4, 5.1 and> 10 fold increase in GI50 values for EKB-569, FED2 and FED6, respectively, in
the ABCB1 overexpressing cell line (Fig 2A) suggesting that all three compounds were effluxed
via ABCB1. Pre-treatment with specific ABCB1 inhibitor, zosuquidar [32], led to a decrease in
the GI50 of EKB-569, FED2 and FED6 in 3T3-MDR1 but not 3T3 cells (Table 2; Fig 2A), con-
firming that the lower cytotoxicity of these compounds in 3T3-MDR1 cells was a result of
efflux of the compounds via ABCB1. Similarly, there was a 1.7, 3.2 and 6.3 fold increase in
GI50 values, for EKB-569, FED2 and FED6, respectively, in the ABCG2 overexpressing cell line
(Fig 2B), suggesting that both FED2 and FED6 were effluxed via ABCG2. Pre-treatment with
specific ABCG2 inhibitor, FTC, led to a decrease in the GI50 of EKB-569, FED2 and FED6 in
Table 2. The effect of cyanoquinoline inhibitors on growth of ABC transporter-proficient or ABC transporter-deficient cell lines.
Drug (GI50 units) MCF7 MCF7MX 3T3 3T3-MDR1
-FTC +FTC -FTC +FTC -Zosuquidar +Zosuquidar -Zosuquidar +Zosuquidar
EKB-569 (μM) 2.61±0.07 2.55±0.04 4.28±0.23 1.54±0.06 1.06±0.6 1.15±0.6 5.75±0.7 2.7±0.8
FED2 (μM) 14.9±8.6 14.8±8.54 27.6±15.9 10.3±5.95 7.0±1.2 4.5±0.8 36.0±1.1 5.9±0.6
FED6 (μM) 12.0±6.93 12.3±7.1 75.9±43.8 37.9±21.9 10.7±1.0 7.8±0.7 >100 13.6±0.6
FED14 (μM) 11.4±1.36 11.2±1.11 6.53±0.34 10.1±0.73 14.8±0.7 14.8±0.7 8.7±0.7 12.2±0.6
Vinblastine (nM) 5.12±0.74 5.36±0.63 2.08±0.41 2.66±0.66 1.8±1.0 1.5±1.2 219±0.8 1.1±1.1
Mitoxantrone (μM) 10.7±6.18 6.62±3.82 2500±1440 22.8±13.1 37.0±0.8 197.0±0.6 141±1.0 57±1.0
Data are expressed as 50% growth inhibitory concentration, GI50 ± SE, determined from SRB cell viability assays in MCF7 and MCF7MX with or without 1 h
pre-treatment with 10 μM FTC and in 3T3 and 3T3-MDR1 with or without pre-treatment with 0.3 μM Zosuquidar. Vinblastine and Mitoxantrone were used as
positive control compounds. FTC and Zosuquidar were used as ABC transporter modulators.
doi:10.1371/journal.pone.0161427.t002
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MCF7MX but not MCF7 (Table 2, Fig 2B) cells confirming that the differential cytotoxicity of
these compounds in the two cell lines were related to efflux via ABCG2.
To confirm if the GI50 ratio’s above predicted radiotracer efflux, we examined the cell uptake
of radiolabelled [18F]FED6 in the same pairs of cell lines above expressing different levels of
ABC transporters. Expectedly, [18F]FED6 uptake was low in ABCB1 and ABCB2 proficient
3T3-MDR1 (0.7 CCPMA/μg of protein) and MCF7MX cells (7.7 CCPMA/μg of protein) com-
pared to isogenic transporter deficient 3T3 (22 CCPMA/μg of protein) and MCF7 cells (81
CCPMA/μg of protein) (Fig 3A and 3B). Furthermore, [18F]FED6 uptake increased 19 fold in
3T3-MDR1 cells following zosuquidar pre-treatment and 4 fold in MCF7MX cells following
FTC pre-treatment, indicating that ABCB1 or ABCG2 antagonism enhances [18F]FED6 uptake.
Finally we examined the efflux of cyanoquinoline compounds in the universally exploited
caco2 transwell assay. EKB-569, FED2, and FED6 showed efflux ratios>3 (Fig 4A), the
accepted threshold for active efflux, indicating active efflux via the ABC transporters [33].
Interestingly, FED14 had an efflux ratio< 1 in keeping with its physicochemical properties
(Fig 1). The efflux ratio of FED6 decreased from 6.9 to 1.1 in the presence of ABC transporter
inhibitor verapamil further confirming the active efflux of this molecule via the ABC transport-
ers (Fig 4B).
Higher Affinity of FED6 for Active Mutant EGFR Did Not Translate into
Higher [18F]FED6 Uptake in Active Mutant EGFR Expressing Cells
The cyanoquinoline compound FED6 had previously been investigated in cells expressing
wildtype EGFR only. We investigated FED6 in the context of mutant EGFR. Inhibition of
EGFR phosphorylation (p-EGFR Y1068) by FED6 was measured. The IC50 value for FED6
Fig 2. Growth inhibitory effect associated with a series of cyanoquinolinemolecules in 3T3, 3T3-MDR1, MCF7, and MCF7MX
cells. A. Ratios of GI50 values in 3T3-MDR1 over GI50 values in 3T3 cells with and without pre-treatment with zosuquidar (zos). B.
Ratios of GI50 values in MCF7MX over GI50 values in MCF7 cells with and without pre-treatment with fumitremorgin C (FTC). Data
indicate mean ratios ± SE of ratios obtained from three separate experiments.
doi:10.1371/journal.pone.0161427.g002
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was significantly lower in active mutant EGFR expressing cell lines at 8–40 nM in H1650 (del
746–750), PC9 (del 746–750) and H3255 (L858R) cells compared to 600–700 nM in wildtype
EGFR expressing A549 and H358 cells; H1975 (L858R/T790M) cells had IC50>1,000 nM (Fig
5A). The in vitro derived del 746-750/T790M cell line (PC9ER) showed a 2-fold higher IC50
value in response to FED6 compared to isogenic (PC9) cells devoid of T790M resistance
mutation.
The highest cell uptake of [18F]FED6 was seen in H3255 cells and lowest in H1650 cells (Fig
5B). Wildtype expressing H358 cells also showed high uptake of [18F]FED6 (86 CCPMA/μg of
protein). The high affinity of FED6 in H1650 cells (low IC50 value) was discordant with the
low [18F]FED6 uptake in these cells; similarly, the low affinity of FED6 for wildtype EGFR
(high IC50 value) in H358 cells was discordant with high uptake of [18F]FED6 in these cells.
EGFR, ABCB1 and ABCG2 protein expression in these cells (Fig 5C) indicated that a lack of
correlation between the affinity of FED6 for the different mutant forms of EGFR and the degree
of cell uptake of [18F]FED6 could be a result of differential expression of EGFR and ABCG2.
Indeed, H3255 cells express significantly higher levels of EGFR than the other cell lines which
could explain the highest uptake of [18F]FED6 in these cells. The lack of ABCG2 in H3255 and
H358 could also explain why the uptake of [18F]FED6 was highest in these two cell lines regard-
less of the EGFRmutational status. As ABCB1 protein expression was not detected in any of the
cell lines studied we focused on the possibility of overcoming the efflux of [18F]FED6 via ABCG2.
Can ABCG2 Knockdown or Inhibition Overcome Reduced Cell Uptake
of Radiolabelled [18F]FED6?
One way of simplifying EGFR-specific tracer uptake interpretation is to remove the contribu-
tion of ABCG2 activity. Thus, we examined the specific role of ABCG2 in the efflux of [18F]
Fig 3. [18F]FED6 uptake in ABC transporter expressing cells. A. Protein normalised uptake of [18F]FED6 in 3T3 and 3T3-MDR1
cells, following 1 h incubation with 0.22MBq of [18F]FED6, with or without pre-treatment with zosuquidar at 0.3 μM for 1 h. B. Protein
normalised uptake of [18F]FED6 in MCF7 and MCF7MX cells, following 1 h incubation with 0.22MBq of [18F]FED6, with or without pre-
treatment with 10 μM fumitremorgin C (FTC) for 1 h. Data are mean ± SE of triplicates, repeated twice. Statistical differences between
data obtained following an unpaired t-test are indicated on graph; (** = P < 0.01).
doi:10.1371/journal.pone.0161427.g003
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FED6 in MCF7MX cells (+++ ABCG2; + EGFR and p-EGFR expression) following ABCG2
siRNA transfection or pre-treatment with ABCG2 inhibitors, FTC and gefitinib. The effect of
FTC (positive control) and gefitinib were examined in isogenic ABCG2 negative MCF7 cells.
[18F]FED6 uptake increased from 0.6 CCPMA/μg protein in scramble siRNA transfected
MCF7MX cells to 3.5, 6 and 6.3 following pre-treatment with ABCG2 siRNA, FTC (positive
control) and gefitinib, respectively (Fig 6A). The lower [18F]FED6 uptake following ABCG2
siRNA pre-treatment compared to FTC or gefitinib could be due to incomplete knockdown of
ABCG2. The cell uptake of [18F]FED6 was unchanged following pre-treatment with FTC or
gefitinib in ABCG2 negative MCF7 cells (Fig 6B). To further scrutinize the specificity of this
approach, we repeated the study in an independent cell line, A431 (+ ABCG2; +++ EGFR and
p-EGFR expression). The high unmodulated [18F]FED6 uptake at baseline could be explained
in part by high EGFR expression (Fig 6C). ABCG2 knockdown was near complete and was
associated with increased [18F]FED6 uptake. FTC and gefitinib again increased [18F]FED6
uptake in this cell line.
Evaluation of a Hydrophilic Cyanoquinoline, FED20
While it is feasible to enhance radiotracer uptake via inhibition of ABCG2, an ultimate goal for
this class of radiotracers is to design out substrate specificity for ABC transporters. As well as
being a substrate for ABCB1 and ABCG2, FED6 is also associated with high non-specific bind-
ing. The high lipophilicity (LogP) of FED6 (3.85) (Fig 1) is thought to contribute at least in
part to this property. We recently reported the synthesis of a glycosylated cyanoquinoline
Fig 4. Efflux ratios of cyanoquinoline compounds in caco2 transwell assay. A. Efflux ratios of selected cyanoquinoline compounds.
B. Efflux ratios of FED6 and vinblastine with or without pre-treatment with 10 mg/mL of verapamil or 10μM of fumitremorgin C (FTC) for 1
h. All data shows mean ± SE of triplicates, repeated twice. Statistically significant differences between data obtained following an unpaired
t-test are indicated on graph; (* = p < 0.05, ** = P < 0.01).
doi:10.1371/journal.pone.0161427.g004
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derivative, FED20, designed to reduce the lipophilicity [31]. The LogP of FED20 was signifi-
cantly lower than that of FED6 at 2.51, while retaining affinity for EGFR; IC50 for inhibition of
cell-free EGFR phosphorylation was 4.5 nM compared to 1.8 nM for FED6 [18,31]. While fea-
tures such as MW, PSA, and n(N+O) were still suggested of active efflux, we predicted that
FED20 would have improved uptake selectivity profile due to the lower LogP [34].
A number of observations indicated that FED20 was not a substrate for ABCB1 or ABCG2
transporters: a) In the MCF7/MCFMX and 3T3/3T3-MDR isogenic cell lines, no biologically
significant differences in uptake of radiolabelled FED20 was seen (Fig 7A and 7B). Further-
more, pre-treatment with specific transporter inhibitors, FTC in the MCF7/MCF7MX cells and
Fig 5. Affinity of FED6 and uptake of [18F]FED6 in NSCLC cell lines. A. IC50 values of FED6 obtained
frommeasuring changes in p-EGFR Y1068 in NSCLC cell lines following incubation with FED6 for 3 h. Data
are mean IC50 ± SE obtained from three separate experiments. B. Protein normalised uptake of [18F]FED6 in
NSCLC cell lines following 1 h incubation with 0.22MBq [18F]FED6. C. Protein expression of total EGFR, and
ABC transporters ABCG2 and ABCB1 in NSCLC cells. MCF7MX and 3T3-MDR1 were used as positive
controls for ABCG2 and ABCB1 expression, respectively.
doi:10.1371/journal.pone.0161427.g005
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zosuquidar in the 3T3/3T3-MDR1 cells, did not lead to an increase in the uptake of [18F]
FED20 in the ABCG2 or ABCB1 expressing cell lines. b) FED20 was not actively effluxed by
caco-2 monolayers, with efflux ratio close to unity (1.3) (Fig 7C). In addition, pre-treatment
with zosuquidar did not have any effect on the permeability ratio. In contrast, the permeability
ratios of vinblastine (positive control), a substrate of ABC transporters, and FED6 (Fig 4) were
greater than 3, the accepted threshold for active efflux; pre-treatment with zosuquidar reduced
the ratio for vinblastine from 6.7 to 1.7 (Fig 4). Expectedly, [18F]FED20 uptake was higher in
A431 cells compared to EGFR lowMCF7 (Fig 7D and 7E). Pre-treatment with unlabelled
FED20 decreased [18F]FED20 uptake in the former but not in the latter cell line. Notably, the
Fig 6. Modulation of [18F]FED6 uptake following ABCG2 knockdown or drug inhibition. Protein
normalised uptake of [18F]FED6 and corresponding protein expression by western blot in A. MCF7MX, B.
MCF7, and C. A431 following 1 h incubation with 0.22MBq [18F]FED6. MCF7MX and A431 cells were
transfected with 25 nM ABCG2- or scrambled-siRNA for 72 h prior to cell uptake. Non-transfected cells were
pre-treated with or without 10 μM fumitremorgin C (FTC) or 10 μM gefitinib for 1 h. Data are mean ± SE from
triplicates, repeated twice. β-actin was used as a loading control. (** = P < 0.01).
doi:10.1371/journal.pone.0161427.g006
ABC Transporter-Independent Imaging of EGFR
PLOSONE | DOI:10.1371/journal.pone.0161427 August 23, 2016 13 / 21
lower overall uptake selectivity of [18F]FED20 in cells could be explained by the hydrophilic
nature of the radiotracer.
Finally, we examined the utility of [18F]FED20 for discriminating isogenic mutant EGFR
cell lines that expressed del E746-A750 EGFR (PC9) or del E746-A750/T790M (PC9ER) for
which [18F]FED6 was not discriminatory. Both cell lines expressed similar levels of EGFR,
however, the IC50 for inhibition of EGFR phosphorylation was 2-fold higher in PC9ER
(0.7μM) compared to PC9 cells (0.3μM) (Fig 8A–8C). The same trend of higher potency in
Fig 7. Cell uptake of [18F]FED20 in relation to ABC transporter substrate specificity and specificity for
EGFR. Protein normalised uptake of [18F]FED20 in A. MCF7 and MCF7MX, or B. 3T3 and 3T3-MDR1
following 1 h incubation with 0.55 MBq of FED20 with or without pre-treatment with 10 μM fumitremorgin C
(FTC) or 0.3 μM zosuquidar (zos) for 1 h. C. Efflux ratio of FED20 and vinblastine from a caco2 transwell
assay with or without 1 h pre-treatment with 10 mg/ml of verapamil. D. Protein normalised uptake of [18F]
FED20 in A431 and MCF7 cells following 1 h incubation with 0.55MBq of [18F]FED20 with or without pre-
treatment with 10 μMFED20. Data are mean ± SE of triplicate, repeated twice. E. Protein expression of p-
EGFR Y1068 and EGFR in A431 and MCF7 cells. (** = P < 0.01).
doi:10.1371/journal.pone.0161427.g007
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PC9 versus PC9ER was seen with gefitinib and FED6 (positive controls) although the magni-
tude of reduction was higher for gefitinib and FED6. In keeping with this observation, the
uptake of [18F]FED20 was higher in the PC9 compared to PC9ER cells (Fig 8D). The overall
lower potency for inhibition of p-EGFR inhibition is also likely due to the hydrophilic character
of the compound. [18F]FED20 uptake was also low in cells harboring EGFR wildtype or
T790Mmutation. The H1650 cell line was unique in that while it harbors del E746-A750 active
mutant EGFR, it showed low [18F]FED20 uptake. The absolute uptake of [18F]FED20 was
improved at higher specific radioactivity (Fig 8E).
Fig 8. Comparative affinities FED20, gefitinib and FED6 in TKI sensitive and resistant NSCLC cell
lines and [18F]FED20 uptake in the cell lines. Typical of p-EGFR Y1068 and EGFR protein expression
following 3 h incubation with increasing concentrations of A. FED20, B. gefitinib, or C. FED6 in PC9 and
PC9ER cells; summary IC50 values for all cell lines determined from densitometry analysis of p-EGFR Y1068
in the western blots are shown. D. Protein normalised uptake of [18F]FED20 in TKI sensitive and resistant
cells following 1 h incubation with 0.55 MBq of [18F]FED20 (low specific activity; 7.3 GBq/μmol). E. Protein
normalised uptake of [18F]FED20 in TKI sensitive and resistant cells following 1 h incubation with 0.74 MBq of
[18F]FED20 (higher specific activity; 52 GBq/μmol). (* = p < 0.05, ** = P < 0.01).
doi:10.1371/journal.pone.0161427.g008
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Discussion
EGFR remains an important transmembrane receptor target in cancer and molecular imaging
of EGFR status—expression or mutation—using PET could aid patient selection for treatment
with novel reversible or irreversible inhibitors. A key threat to developing successful imaging
agents is existence and evolution of multidrug resistance phenotype. Starting from the ABC
transporter substrate [18F]FED6, we describe a novel cyanoquinoline radiotracer [18F]FED20
that is devoid of ABC transporter activity.
One of the key components of MDR is the increase in expression of ABC transporters
[35,36]. In the context of PET imaging, ABC transporter substrate specificity is also an impor-
tant mechanism of radioprobe clearance. Indeed, as only tracer amounts of the radiolabelled
probe are injected into the patients, efflux via such transporters will significantly decrease the
potential accumulation of the radiotracer in the tumour. Several TKIs, including EKB-569
from which the FED series of compounds are derived have been shown to be substrates for
members of the ABC transporter family [24]. The initial in silico characterisation of the FED
series of compounds, indicated that these compounds had several characteristics which make
them potential substrates for both ABCB1 and ABCG2 transporters: MW above 400 Da,
LogP> 3 (ABCB1 substrate) and PSA>85Å2 (ABCG2 substrate). [37,38]. We therefore pre-
dicted that FED6, FED2, and FED9 would be substrates for ABCB1 and ABCG2, whereas
FED14 that had a lower MWwould not. The cell viability assays performed in the paired cells
lines that are proficient or deficient for specific ABC transporters, allowed us to indirectly ver-
ify this prediction. The higher GI50 values of FED6 in both the ABCB1 expressing 3T3-MDR1
cells and the ABCG2 expressing MCF7MX cells compared to the paired matched cells that
expressed no transporters, as well as decreases in GI50 when the transporters were inhibited
with zosuquidar or FTC indicated substrate specificity of FED6 for both transporters. By mea-
suring efflux ratios, corresponding to the ratio between the rate of secretion over the rate of
absorption, we determined that FED6, together with EKB-569, and FED2 were indeed effluxed
by the physiologically relevant differentiated caco2 cell model; efflux ratios above 1 were indic-
ative of active ABC transporter efflux [33]. The efflux of FED6 was reduced in the presence of
ABC transporter inhibitor verapamil further confirming the active efflux of FED6. The indirect
measurement of cytotoxicity in paired cells, compound efflux in caco2 and modulation by
pharmacological inhibitors translated into predicted differences in [18F]FED6 uptake in the
ABC transporter proficient versus deficient cells.
EGFR is overexpressed in several cancers including, breast, ovarian, brain and colorectal [39],
and this has led to development of specific TKIs directed against EGFR. However, efficacy of gefi-
tinib and erlotinib against wildtype EGFR in patients was disappointing, with only a small frac-
tion of unselected patients responding to TKI treatment [40]. The subgroup of patients, shown to
express active mutant EGFR, had significantly higher response rates to TKI treatment [10]. Iden-
tifying patients that express mutant EGFR, non-invasively via PET imaging could assist in thera-
peutic selection. To date no PET tracers have been approved for the imaging of either wildtype or
mutant EGFR in the clinic. The discovery of [18F]PEG6-IPQA, an L858R mutant EGFR specific
[18F] PET radiotracer that showed a 7.6 fold higher uptake in H3255 (L858REGFR) compared
to H1975 (L858R/T790M EGFR) xenografts was an important breakthrough in the imaging of
EGFR [19]. This radiotracer was only studied in L858R mutant EGFR and further investigation
in other common active mutant EGFR, including del E746-A750 EGFR would be important. Fur-
thermore, tumour uptake of the most recent iteration of irreversible EGFR imaging agents, [18F]
afatinib, was sensitive to modulation by the ABCB1-specific inhibitor, tariquidar.
We investigated [18F]FED6 for the imaging of mutant EGFR. FED6 was more potent
against active mutant EGFR expressing cells than wildtype or resistant mutant EGFR
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expressing cells with respect to inhibition of p-EGFR. The uptake of [18F]FED6 was high in
H3255 (L858R EGFR) and the PC9 (del E746-A750) cells, and lowest in gefitinib resistant
H1650 (del 746–750) and H1975 cells (L858R/T790M) cells. The higher uptake of [18F]FED6
in H3255 cells as opposed to the low uptake in H1975 cells correlated with the differential
affinity of FED6 in these two cells lines, assessed by western blot. However, it is important to
note that expression levels of EGFR as well as mutant status could impact on the uptake of
[18F]FED6. H3255 cells had the highest expression of EGFR compared to the other NSCLC
cell lines investigated. We cannot claim that the higher uptake of [18F]FED6 in H3255 cells is
a consequence of the higher affinity of FED6 for L858R mutant EGFR since it could also be
due to higher expression of EGFR or a combination of these. We addressed this conundrum
by assessing uptake of [18F]FED6 in isogenic PC9 and PC9ER cell lines that have the same lev-
els of EGFR protein expression but differ in mutational status; no statistical difference in the
uptake of [18F]FED6 was seen. Furthermore, the low uptake of [18F]FED6 in H1650 cells was
at odds the potent reduction of p-EGFR by FED6 in these cells. Notably, ABCB1 was not
expressed in any of the cell lines studied, whereas ABCG2 was expressed in all the cell lines
with the exception of the H3255 and H358 cells. Therefore the higher uptake of [18F]FED6 in
H3255 and H358 compared to the low uptake in A549 and H1650 could also be related to
expression of ABCG2.
As only ABCG2 was expressed in the cell lines used, we wondered whether it would be feasi-
ble to improve EGFR detection properties of [18F]FED6 by blocking this transporter using
siRNA or pharmacological inhibitors FTC and gefitinib [41–44]. Indeed, both siRNA and
pharmacological inhibition of ABCG2 increased [18F]FED6 uptake with magnitude depending
on ABCG2 expression/knockdown and EGFR expression. The uptake of [18F]FED6 following
inhibitor pre-treatment was consistently higher than following ABCG2 siRNA transfection
which could be due to more efficient inhibition by the compounds. Rather than having to
block the effect of the ABC transporters to which [18F]FED6 is a substrate, designing a radio-
tracer than lacks the ABC transporter substrate specificity is preferred.
We have recently reported a hydrophilic cyanoquinoline compound FED20 [31]. The addi-
tion of a glucose moiety to form FED20 reduced LogP (to 2.1) compared to that of FED6
(3.85). The higher uptake of [18F]FED20 in the A431 versus MCF7 cells was indicative of the
specificity of the tracer for EGFR. Furthermore, the uptake of [18F]FED20 in isogenic ABCB1
and ABCG2 proficient or deficient cell lines, supported by the unremarkable efflux characteris-
tics of unlabelled FED20 by differentiated caco2 cells indicated that the compound lacked sub-
strate specificity for ABCB1 and ABCG2. We have not tested the impact of all known ABC
transporters in this study. For example, we did not directly test the impact of ABCC1 (MRP1)
expressed in NSCLC as a potential risk for interaction with FED6. Even though no isogenic cell
line information was generated for MRP1, the caco-2 data are broadly suggestive of a lack of
interaction. Furthermore, verapamil is a dual ABCB1-MRP1 inhibitor, thus, a lack of interac-
tion could be inferred from the verapamil inhibitor data [45,46]. The magnitude of [18F]FED20
uptake was> 5-fold lower than that seen for [18F]FED6. Despite its lower lipophilicity, this
result is counterintuitive given the lack of transporter activity. The lower potency of FED20 on
p-EGFR compared to FED6 suggests that the lower lipophilicity of FED20 may somewhat com-
promise its cellular delivery and engagement of target. An additional potential reason for the
low [18F]FED20 uptake is lower specific activity (7.3 GBq/μM) of the reported radiosynthetic
method [31] compared to [18F]FED6 (48 GBq/μmol) with some self-blocking by cold com-
pound being a possibility. In keeping with this hypothesis, absolute uptake of [18F]FED20
increased at higher specific radioactivity (52 GBq/μmol) although the difference in uptake
between PC9 and PC9ER was less (albeit significant) than seen under low specific activity
conditions.
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In view of the lack of ABC transporter substrate specificity, we investigated the potential of
this tracer for the imaging of mutant versus wild type EGFR. We initially focused on two cell
lines with nearly equivalent EGFR expression and for which [18F]FED6 uptake was non-dis-
criminatory; PC9 cells expressing active mutant EGFR had a 2-fold higher uptake of [18F]
FED20 compared to PC9ER cells. [18F]FED20 uptake was also low in other cells harboring
EGFR wildtype or T790M mutation except the H1650 cell line, which while harboring a del
E746-A750 active mutant EGFR, showed low [18F]FED20 uptake. Despite harboring active
mutant EGFR, this cell line is known to be resistant to gefitinib. PTEN loss has been proposed
as a key genomic resistance mechanism in the cell line [47], but it is unclear if this alteration
affects cellular ATP levels or ATP affinity of the EGFR receptor in addition to the known activ-
ity of PTEN loss/AKT activation in cell survival.
So far we have demonstrated that [18F]FED20 has useful properties for discriminating
EGFR inhibitor resistance (genomic or functional) in NSCLC cell lines. Further work—in par-
ticular metabolism, biodistribution and imaging contrast—is required to advance [18F]FED20
towards imaging in humans for upfront detection of mutational status, monitoring response to
treatment, and assessing the development of drug resistance [16,48]. The current recommen-
dations are that, NSCLC patients undergo screening for mutations to EGFR before the start of
therapy [49]. This allows the selection of patients with active mutant to be given TKI gefitinib
or erlotinib. Indeed gefitinib was approved in the UK by NICE in 2009 for first line treatment
for advanced metastatic NSCLC with active mutant EGFR [50]. PET imaging of active mutant
EGFR could complement this screening as biopsies are not always possible and different nod-
ules may present different mutational expression that would not be picked up if one site was
biopsied [51]. PET may also be useful in detecting secondary resistance.
Conclusion
We demonstrated the role of the substrate specificity of the cyanoquinoline compound FED6
in the low accumulation of the radiotracers in the tumour. Blocking ABCG2 with gefitinib led
to an increase in [18F]FED6 uptake. FED20, which lacked substrate specificity for ABCB1 and
ABCG2 was found to have favourable properties for detection of EGFR resistance.
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